Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 12/20 | 0.64 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.62 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.62 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emakalim SCHEMBL9142302 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL4258884 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL7273953 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL231719 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL8084996 | 0.91 | ABCC9 (0.53) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL7267817 | 0.87 | ABCC9 (0.52) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL7274507 | 0.87 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Emakalim SCHEMBL5047102 | 0.87 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL8084602 | 0.86 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL7273811 | 0.86 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | ABCC9 633/4885ABCC8 1479/4885KCNJ11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.